Suppr超能文献

血管生成抑制剂SU6668联合5-氟尿嘧啶对人结直肠癌移植瘤裸鼠肝转移的影响

Effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from transplantation tumors of human colorectal cancer in nude mice.

作者信息

Ge Yunfei, Ding Yinlu, Zhang Jianliang, Li Zhanyuan, Li Zhaoting

机构信息

Department of General Surgery, The Second Hospital of Shandong University Jinan 250033, China.

Department of General Surgery, Qilu Hospital of Shandong University Jinan 250012, China.

出版信息

Int J Clin Exp Med. 2014 Oct 15;7(10):3578-82. eCollection 2014.

Abstract

This study was to investigate inhibiting effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from human colon cancer. Results showed that metastasis rates in SU6668+5-Fu group, SU6668 group, 5-Fu group decreased obviously (P<0.01). Compared with 5-Fu group and control group, microvessel density significantly decreased in SU6668+5-Fu group and SU6668 group (P<0.05). Vascular endothelial growth factor and base fibroblast growth factor reduced obviously in SU6668+5-Fu group, SU6668 group and 5-Fu group compared with control group, and there were significant differences among SU6668+5-Fu group, SU6668 group and 5-Fu group (P<0.05). Thus, SU6668 can inhibit liver metastasis from colorectal cancer through anti-angiogenesis, and it would have a synergistic effect in combination with 5-Fu. Therefore, SU6668 combined with 5-Fu could be considered as a safe and effective antitumor strategy.

摘要

本研究旨在探讨血管生成抑制剂SU6668联合5-氟尿嘧啶对人结肠癌肝转移的抑制作用。结果显示,SU6668+5-氟尿嘧啶组、SU6668组、5-氟尿嘧啶组的转移率明显降低(P<0.01)。与5-氟尿嘧啶组和对照组相比,SU6668+5-氟尿嘧啶组和SU6668组的微血管密度显著降低(P<0.05)。与对照组相比,SU6668+5-氟尿嘧啶组、SU6668组和5-氟尿嘧啶组的血管内皮生长因子和碱性成纤维细胞生长因子明显降低,且SU6668+5-氟尿嘧啶组、SU6668组和5-氟尿嘧啶组之间存在显著差异(P<0.05)。因此,SU6668可通过抗血管生成抑制结直肠癌肝转移,且与5-氟尿嘧啶联合具有协同作用。所以,SU6668联合5-氟尿嘧啶可被视为一种安全有效的抗肿瘤策略。

相似文献

6
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Radiat Res. 2002 Jan;157(1):45-51. doi: 10.1667/0033-7587(2002)157[0045:taasas]2.0.co;2.

引用本文的文献

1
Metadherin regulates epithelial-mesenchymal transition in carcinoma.
Onco Targets Ther. 2016 Apr 21;9:2429-36. doi: 10.2147/OTT.S104556. eCollection 2016.
2
Multi-kinase inhibitors, AURKs and cancer.
Med Oncol. 2016 May;33(5):43. doi: 10.1007/s12032-016-0758-4. Epub 2016 Apr 1.
3
Incidence and risk factors of chylous ascites after pancreatic resection.
Int J Clin Exp Med. 2015 Mar 15;8(3):4494-500. eCollection 2015.

本文引用的文献

1
Protein kinase inhibitor SU6668 attenuates positive regulation of Gli proteins in cancer and multipotent progenitor cells.
Biochim Biophys Acta. 2014 Apr;1843(4):703-14. doi: 10.1016/j.bbamcr.2014.01.003. Epub 2014 Jan 10.
5
Quality assurance in rectal cancer treatment in the Netherlands: a catch up compared to colon cancer treatment.
Eur J Surg Oncol. 2010 Apr;36(4):340-4. doi: 10.1016/j.ejso.2009.10.010. Epub 2009 Nov 26.
6
Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas.
Br J Cancer. 2009 May 19;100(10):1575-80. doi: 10.1038/sj.bjc.6605041. Epub 2009 Apr 21.
7
Effect of splenectomy on antitumor immune system in mice.
Anticancer Res. 2009 Jan;29(1):385-93.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验